Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

September 01, 2025

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

News Daily News

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

May 16, 2025

Patchy Anticoagulation Use During COVID Pandemic Raises Questions

News Daily News

Patchy Anticoagulation Use During COVID Pandemic Raises Questions

March 06, 2025

IVC Filter Lawsuits Expose Holes in FDA Oversight and Public Communication

News Daily News

IVC Filter Lawsuits Expose Holes in FDA Oversight and Public Communication

December 03, 2024

November 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

November 26, 2024

PEERLESS: FlowTriever Tops Catheter-Directed Thrombolysis for Acute PE

News Conference News TCT 2024

PEERLESS: FlowTriever Tops Catheter-Directed Thrombolysis for Acute PE

October 29, 2024

AI in Pulmonary Embolism: ‘Transformative’ for Patient Care

News Conference News ISET 2024

AI in Pulmonary Embolism: ‘Transformative’ for Patient Care

January 30, 2024

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

Hints of Benefit With Catheter-Directed Thrombolysis in Intermediate/High-Risk PE

News Daily News

Hints of Benefit With Catheter-Directed Thrombolysis in Intermediate/High-Risk PE

October 19, 2022

Shorter Anticoagulation an Option for Young Patients With Provoked VTE

News Daily News

Shorter Anticoagulation an Option for Young Patients With Provoked VTE

January 11, 2022

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

News Conference News

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

November 15, 2021

Long-term Anticoagulation After Unprovoked VTE: New Insights

News Daily News

Long-term Anticoagulation After Unprovoked VTE: New Insights

September 13, 2021

Anticoagulation Use Quickly Rose to Meet COVID-19 Need

News Daily News

Anticoagulation Use Quickly Rose to Meet COVID-19 Need

June 14, 2021

VTE Related to SARS-CoV-2 Infection Less of a Problem in Outpatients

News Daily News

VTE Related to SARS-CoV-2 Infection Less of a Problem in Outpatients

April 06, 2021

In COVID-19 Pulmonary Embolism, Nontraditional Risk Factors Dominate

News Daily News

In COVID-19 Pulmonary Embolism, Nontraditional Risk Factors Dominate

Yael L. Maxwell

July 21, 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

News Conference News ACC 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

April 01, 2020

Future Pulmonary Embolism Interventions: Wild West or Working Together?

News Conference News VIVA 2019

Future Pulmonary Embolism Interventions: Wild West or Working Together?

November 14, 2019

Interventional Options and Future Directions for Acute PE: New AHA Statement

News Daily News

Interventional Options and Future Directions for Acute PE: New AHA Statement

October 07, 2019

Off Script: Through ‘Paclitaxelgate,’ Some Upsides to Uncertainty

News Opinion Off Script

Off Script: Through ‘Paclitaxelgate,’ Some Upsides to Uncertainty

Sahil Parikh, MD

July 29, 2019

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

August 26, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.